Commonly prescribed pain drug can increase your risk of dementia by up to 40%
The anti-seizure drug gabapentin is used to treat epilepsy, nerve pain after shingles and restless legs syndrome by affecting chemical messengers in the brain and nerves.
Common side effects include dizziness, drowsiness, headaches and nausea. Now, a new study out of Case Western Reserve University in Cleveland warns that gabapentin can significantly increase the risk of dementia and mild cognitive impairment in people taking it for chronic low back pain.
4 A new study warns that gabapentin can significantly increase the risk of dementia and mild cognitive impairment in people taking it for chronic low back pain.
ryanking999 – stock.adobe.com
'Our findings indicate an association between gabapentin prescription and dementia or cognitive impairment within 10 years. Moreover, increased gabapentin prescription frequency correlated with dementia incidence,' the study authors wrote this week in the journal Regional Anesthesia & Pain Medicine.
Researchers pored over records of 26,400 patients who had been prescribed gabapentin for persistent low back pain between 2004 and 2024 and 26,400 patients who didn't get a prescription.
After taking into account patient demographics, their medical history and their use of other painkillers, the researchers determined that those who had received six or more gabapentin prescriptions were 29% more likely to be diagnosed with dementia.
This same group was also 85% more likely to be diagnosed with mild cognitive impairment within 10 years of their back pain diagnosis.
4 The anti-seizure drug gabapentin is used to treat epilepsy, nerve pain after shingles and restless legs syndrome by affecting chemical messengers in the brain and nerves.
The Drug Users Bible
Dementia tends to affect older adults, yet the risks of dementia more than doubled among 35- to 49-year-olds prescribed gabapentin.
Their risks of mild cognitive impairment more than tripled.
Similar effects were seen in patients 50 to 64 years old.
Frequency of use was an important factor, too.
People with 12 or more prescriptions were 40% more likely to develop dementia and 65% more likely to develop mild cognitive impairment than those prescribed gabapentin three to 11 times.
Gabapentin was approved by the US Food and Drug Administration in 1993 to control partial seizures in epilepsy patients older than 12.
4 Gabapentin was approved by the US Food and Drug Administration in 1993 to control partial seizures in epilepsy patients older than 12.
W.carter/Wikimedia Commons
Unlike opioids, gabapentin was initially considered to have a low potential for abuse or dependence.
However, there's growing concern about its misuse, particularly to enhance opioid highs.
With this new research, the study authors acknowledged that their work was observational, so they could not definitively establish a cause-and-effect relationship between gabapentin and dementia.
They also noted that they weren't able to account for gabapentin dose or length of use in their records review.
Still, they said their 'results support the need for close monitoring of adult patients prescribed gabapentin to assess for potential cognitive decline.'
4 Dementia, which affects over 6 million Americans, is characterized by troubles with memory, problem-solving, judgment and language.
LIGHTFIELD STUDIOS – stock.adobe.com
Other medical experts cautioned against drawing overly strong conclusions from the findings.
'While authors used statistical methods to try and account for other risk factors, this type of study cannot prove that gabapentin was the cause of increased dementia risk,' Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh in Scotland, told reporters.
'One very important factor that was not examined in this study is levels of physical activity,' she added. 'People with chronic pain requiring gabapentin may have been less physically active, which is a known risk factor for developing dementia.'
Other known risk factors for dementia include traumatic brain injury, untreated hearing loss, depression, high blood pressure, diabetes, obesity and a history of smoking.
Experts recommend lowering dementia risk with a healthy diet, regular exercise and social activity and without cigarettes or excessive alcohol.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Vertex plan to build on pain drug breakthrough hits hurdles
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals made its name and fortune by developing ever more effective medicines for the rare disease cystic fibrosis. On Monday, the biotechnology company disclosed two setbacks that suggest one of its next targets for a similarly iterative approach to innovation, pain, may not go as smoothly as it and investors had hoped. Alongside earnings for the second quarter, Vertex disclosed that a successor drug to its pioneering pain medicine Journavx, which was approved this January in the U.S., failed to meet its main goal in a mid-stage clinical trial. As a result, Vertex will no longer advance this follow-on compound, dubbed VX-993, into pivotal testing for acute pain treatment on its own. At the same time, Vertex informed investors it would not start a late-stage study of Journavx in a form of sciatica, after the Food and Drug Adminsitration indicated an expanded approval in peripheral neuropathic pain would be unlikely. The company had aimed to use data from testing in sciatica and an ongoing study in diabetic neuropathy to widen Journavx's use beyond the acute pain indication it currently holds. 'While a broad [peripheral neuropathic pain] label remains our goal, at this time the FDA does not see a path to a broad indication as such,' said CEO Reshma Kewalramani on a Monday evening call with investors. Instead, Vertex will start a second Phase 3 trial in diabetic neuropathy to eventually support an approval application there. According to estimates recently cited by Vertex, about 2.4 million people in the U.S. have diabetic neuropathy — about one-fifth the 11 million or so people who have peripheral neuropathic pain, which includes sciatica and other types of chronic nerve pain. Shares in Vertex fell by more than 14% in post-market trading Monday on the news, which, if sustained, would translate to erasure of about $17 billion in market capitalization. Pain is one of many research directions Vertex is pursuing as it seeks to become bigger than the cystic fibrosis medicines that made it one of biotech's most valuable companies. But it's arguably the company's highest profile bet, as Journavx offers an alternative to the powerful, but dangerously addictive opioid painkillers that have claimed hundreds of thousands of lives in the U.S. Journavx works differently, in ways that are not thought to be similarly habit-forming. While the medicine proved effective at dulling the sharp and stabbing pain that can occur after surgeries like a bunion removal or 'tummy tuck,' data from testing showed it to be about as potent as a weak opioid. Still, analysts have penciled in billions of dollars for future Journavx sales, seeing a large market in post-surgery therapy that could later be expanded to include chronic pain treatment. Getting to that goal now looks like it will require more time and more testing. Vertex aims to finish enrolling both diabetic neuropathy studies by the end of next year and intends to keep engaging the FDA on paths toward an expansive peripheral neuropathic pain label. In a note to clients, RBC Capital Markets analyst Brian Abrahams said Monday's update eliminates a 'blue sky' scenario for Vertex. The study failure for VX-993, meanwhile, weakens Vertex's argument that the company can improve on Journvax's effectiveness with successive compounds, as it did in cystic fibrosis. The news, Abrahams wrote, 'reduces any potential halo effect around the pain franchise and underscores that it may be more challenging than some expected to iterate and improve upon [Journavx].' Paul Matteis, an analyst at Stifel, told his bank's clients in a separate note that VX-993's failure hints Vertex 'may have nearly maximized the efficacy' it can extract from the way Journavx works, which is by blocking pain-regulating proteins known as NaV1.8. Kewalramani acknowledged that possibility on Monday's call. 'The outcome of the study combined with the totality of evidence from our preclinical models and previous NaV1.8 inhibitor clinical studies in acute pain suggest we are at the high end of the NaV1.8 dose response curve for acute pain in the post-bunionectomy setting.' Vertex continues to enroll a Phase 2 study testing VX-993 in diabetic neuropathic pain. And it could still combine the compound with other molecules that target a related protein called NaV1.7. Yet the setbacks mean investor focus will fall more squarely on Journavx's performance on the market. There, Vertex reported $12 million in sales during the three-month period between April and June, beating Wall Street forecasts by several million dollars. More than 111,000 prescriptions have been written for the drug since it became available at pharmacies in early March, Vertex said. Recommended Reading A new, non-opioid pain drug is here. Getting it to patients could be agony. Sign in to access your portfolio
Indianapolis Star
7 days ago
- Indianapolis Star
Does your energy drink contain booze? Mislabeled Celsius cans included in recall
Celsius energy drinkers might want to check their cans before consuming. Some cans mislabeled as Celsius Astro Vibe Sparkling Blue Razz Edition, a non-alcoholic energy drink, actually contain vodka and were included in High Noon's Beach Variety 12-packs. High Noon said it initiated a recall of the variety packs after it discovered that a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon. The announcement was posted on the US Food and Drug Administration's website. "Consumption of the liquid in these cans will result in unintentional alcohol ingestion," the company said. High Noon said the recalled packs were sent to stores in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin between July 21 and July 23. No illnesses have been reported in connection with the recall at this time, according to High Noon. In an emailed statement to USA TODAY, a spokesperson for High Noon said the company is working with officials to manage the recall. "We are working with the FDA, retailers, and distributors to proactively manage the recall to ensure the safety and well-being of our consumers," the statement reads. The company is advising those who didn't purchase a High Noon Beach variety pack to ensure their Celsius Astro Vibe Sparkling Blue Razz Edition drinks do not contain the lot codes of the recalled products (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) before consuming. Consumers are also advised to throw out the Celsius Astro Vibe Sparkling Blue Razz Edition cans with the impacted lot codes (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) and not drink the liquid, according to the company. High Noon Beach Variety packs with different lot codes than those that are part of the recall are safe to consume, the company added. Anyone who bought the recalled High Noon Beach variety 12-packs or mislabeled Celsius Astro Vibe Sparkling Blue Razz Edition drinks should contact High Noon Consumer Relations at consumerrelations@ to get more information on next steps, including refunds.
USA Today
30-07-2025
- USA Today
High Noon recalls vodka seltzers mislabeled as Celsius energy drinks
Some Celsius energy drinkers could have gotten a boozy surprise, leading to a recall, according to an announcement posted on the US Food and Drug Administration's website. According to the announcement, High Noon said it would be recalling its Beach Variety 12-packs after they said some cans were mislabeled as Celsius Astro Vibe Sparkling Blue Razz Edition cans, which are a non-alcoholic energy drink. "Consumption of the liquid in these cans will result in unintentional alcohol ingestion," the company said. High Noon said the mistake was made after some of the Celsius cans were filled with the alcoholic beverage and mislabeled. The company added that the recalled packs were sent to stores in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin between July 21 and July 23. The recall was initiated after High Noon discovered that a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon, the company said. No illnesses have been reported in connection with the recall at this time, according to High Noon. What is High Noon doing to remedy the recalled drinks? In an emailed statement to USA TODAY, a spokesperson for High Noon said the company is working with officials to manage the recall. "We are working with the FDA, retailers, and distributors to proactively manage the recall to ensure the safety and well-being of our consumers," the statement reads. Recalled High Noon drinks lot codes, product description What to do if you bought the recalled drinks The company is advising those who didn't purchase a High Noon Beach variety pack to ensure their Celsius Astro Vibe Sparkling Blue Razz Edition drinks do not contain the lot codes of the recalled products (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) before consuming. Consumers are also advised to throw out the Celsius Astro Vibe Sparkling Blue Razz Edition cans with the impacted lot codes (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) and not drink the liquid, according to the company. High Noon Beach Variety packs with different lot codes than those that are part of the recall are safe to consume, the company added. Anyone who bought the recalled High Noon Beach variety 12-packs or mislabeled Celsius Astro Vibe Sparkling Blue Razz Edition drinks should contact High Noon Consumer Relations at consumerrelations@ to get more information on next steps, including refunds. Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at and follow him on X @fern_cerv_.
